 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| PSID Firefly DX Detects Flu in Rapid Test and Can Help Save Lives |
|
 Hot Stock to Watch |
Company: PositiveID Corporation (Pink Sheets: PSID)
|
Last:
Price: 0.0016
Change (%): + 0.0001 (6.67)
Volume: 9,151,971 |
 |
PositiveID’s FireflyDX Prototype Detects Flu Types; Chief Science Officer Explains Why Accurate Flu Detection at Point of Care Enables Smart Treatment Decisions in Interview with SmallCapVoice.com
AUSTIN, Texas, Jan. 31, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. today announced it conducted a new audio interview with PositiveID Corporation (“PositiveID” or the “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, regarding the Company’s successful detection of the influenza virus on its FireflyDX real-time polymerase chain reaction (PCR) breadboard prototype system (“prototype system”). The interview can be heard at https://smallcapvoice.com/blog/1-30-18-smallcapvoice-interview-with-positiveid-corporation-psid.
In the interview, Dr. Kimothy Smith, Chief Science Officer of PositiveID and its ExcitePCR Corporation subsidiary, announced the Company’s successful detection of the influenza virus on its FireflyDX prototype system and its publication of a white paper. Smith described the limitations of current rapid influenza detection tests, and discussed how FireflyDX could enable correct diagnosis at the point of care for smart treatment decisions. PositiveID and ExcitePCR are developing FireflyDX, in both portable and handheld forms, to enable fast, accurate diagnosis at the point of care or point of need (POC/PON).
The FireflyDX family of products, currently under development, is designed to provide accurate, rapid pathogen detection using real-time PCR in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems. Current solutions for accurately identifying potential pathogens and bio-threats, especially at the POC/PON, can sometimes take as long as several hours to several days to provide results, dramatically delaying what is often life-saving treatment. Five different flu virus assays (Type A; Type B; H3N3; H7N1; and, H5N1) were tested on the FireflyDX prototype system in the lab.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
